Moderna Disables Comments On X Post Announcing New Covid Shot Amid Backlash

Moderna shares rose in premarket trading after the company announced FDA approval of its new lower-dose Covid-19 vaccine, mNEXSPIKE, for adults aged 65 and older, as well as individuals 12–64 with underlying health conditions. However, the approval sparked backlash on X, with many questioning the Trump administration and Health Secretary Robert F. Kennedy Jr.’s “MAHA” (Make America Healthy Again) agenda.

Moderna said in a Saturday morning X post that the mNEXSPIKE (mRNA-1283) vaccine should be available in the U.S. in time for the 2025-26 respiratory virus season, which starts later this year. 

Share

Leave a Comment

Scroll to Top